ReviewCell adhesion & migration
MUC1 and metastatic cancer: expression, function and therapeutic targeting.
Review in Cell adhesion & migration. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 3 syntheses or guidelines pooled it, 187 citations in OpenAlex.
- Prognostic factors for intraductal papillary neoplasm of the bile duct following surgical resection: a systematic review and meta-analysis.Surgery today · 2025Pooled it
- Serum Krebs von den Lungen-6 before treatment predicts the prognosis of lung cancer in Asian populations: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis.Medicine · 2019Pooled it
- Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma.Cancer immunology, immunotherapy : CII · 2026Article
- MUC1-targeted CAR-T cell secreted anti-PD-1 IgG antibody enhances antitumor activity in Cholangiocarcinoma.Scientific reports · 2026Article
- Kidney Stone History and Survival Outcomes in Upper Tract Urothelial Carcinoma.JAMA network open · 2025Article
- Balancing Antigen Loading on Gold Nanoparticles: Implications for Future Cancer Vaccine Strategies.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Regulatory effects of lncRNA PVT1 on transcriptome in human breast cancer MDA-MB-231 cell line determined by in silico analyses.Chromosoma · 2025Article
- Simple recombinant monoclonal antibody production fromOpen biology · 2025Article
- Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients.Frontiers in oncology · 2025Article
- Machine learning and gene network integration reveal prognostic subnetworks and biomarkers in pancreatic cancer.Computational and structural biotechnology journal · 2025Article
- Genetically surface-modifiedBiotechnology reports (Amsterdam, Netherlands) · 2024Article
- The Formation of Stable Lung Tumor Spheroids during Random Positioning Involves Increased Estrogen Sensitivity.Biomolecules · 2024Article
- Variables Affecting CA15.3 Tumor Antigen Expression and Antibodies against It in Female National Health and Nutritional Survey Participants.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Single-cell analysis of breast cancer metastasis reveals epithelial-mesenchymal plasticity signatures associated with poor outcomes.The Journal of clinical investigation · 2024Article
- Bulky glycocalyx drives cancer invasiveness by modulating substrate-specific adhesion.PNAS nexus · 2024Article
- Harnessing virus flexibility to selectively capture and profile rare circulating target cells for precise cancer subtyping.Nature communications · 2024Article
- Article
- NSUN2 affects diabetic retinopathy progression by regulating MUC1 expression through RNA mJournal of translational medicine · 2024Article
- CD44 in Bladder Cancer.Cancers · 2024Review
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MUC1 is a transmembrane mucin that is often overexpressed in metastatic cancers and often used as a diagnostic marker for metastatic progression. The extracellular domain of MUC1 can serve as a ligand for stromal and endothelial cell adhesion receptors, and the cytoplasmic domain engages in several interactions that can result in increased migration and invasion, as well as survival. In this review, we address the role of MUC1 in metastatic progression by assessing clinical studies reporting MUC1 levels at various disease stages, reviewing mouse models utilized to study the role of MUC1 in metastatic progression, discuss mechanisms of MUC1 upregulation, and detail MUC1 protein interactions and signaling events. We review interactions between MUC1 and the extracellular environment, with proteins colocalized in the plasma membrane and/or cytoplasmic proteins, and summarize the role of MUC1 in the nucleus as a transcriptional cofactor. Finally, we review recent publications describing current therapies targeting MUC1 in patients with advanced disease and the stage of these therapies in preclinical development or clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.